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Abstract
Background: Prognostic factors in predicting occult lymph node metastasis in patients with head and neck
squamous-cell carcinoma (HNSCC) are necessary to improve the results of the sentinel lymph node procedure in
this tumour type. The E-Cadherin glycoprotein is an intercellular adhesion molecule in epithelial cells, which plays
an important role in establishing and maintaining intercellular connections.
Objectives: To determine the value of the molecular marker E-Cadherin in predicting regional metastatic disease.
Methods: E-Cadherin expression in tumour tissue of 120 patients with HNSCC of the oral cavity and oropharynx
were evaluated using the tissue microarray technique. 110 tumours were located in the oral cavity (91.7%; mostly
tongue), 10 tumours in the oropharynx (8.3%). Intensity of E-Cadherin expression was quantified by the Intensity
Reactivity Score (IRS). These results were correlated with the lymph node status of biopsied sentinel lymph nodes.
Univariate and multivariate analysis was used to determine statistical significance.
Results: pT-stage, gender, tumour side and location did not correlate with lymph node metastasis. Differentiation
grade (p = 0.018) and down regulation of E-Cadherin expression significantly correlate with positive lymph node
status (p = 0.005) in univariate and multivariate analysis.
Conclusion: These data suggest that loss of E-cadherin expression is associated with increased lymhogeneous
metastasis of HNSCC. E-cadherin immunohistochemistry may be used as a predictor for lymph node metastasis in
squamous cell carcinoma of the oral cavity and oropharynx.
Level of evidence: 2b
Keywords: Head and Neck squamous cell carcinoma (HNSCC), oral cavity, oropharynx, E-Cadherin (ECAD), Immu-
nohistochemistry, Sentinel node biopsy
Background
Head and neck squamous cell carcinoma (HNSCC) is
the fifth most common malignancy worldwide. In 1999,
in the US, approximately 29’800 patients suffered from a
squamous cell carcinoma of the oropharynx and the
oral cavity and more than 8000 died of it [1]. Despite
improvements in surgical treatment and radiation tech-
nology over the last decades, prognosis remains dismal
in advanced cases. Regional metastatic disease is known
to reduce recurrence free survival and disease specific
survival significantly [2].
A chief feature of malignant behavior is the capability
of tumour cells to metastasize. Metastatic spread is an
extremely bad prognostic factor and responsible for
cause of death in ~90% of all cancer patients [3]. The
cellular mechanisms responsible for the acquisition of a
metastatic phenotype include the adaptation to potential
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hostile environment (blood stream, lymph nodes, organ
of metastasis). In addition, the “tumour cell-to-tumour
cell” and “tumour cell-to-stromal environment” cross
talk is recognized as an important condition for invasion
and metastasis.
Sentinel node biopsy (SNB) for the cN0 neck in early
HNSCC of the oral cavity has been validated by multiple
studies. The workup of sentinel lymph nodes is per-
formed as described elsewhere [4] and reliably detects
occult metastatic disease. Further, occult metastatic dis-
ease is subdivided in macrometastasis (>2 mm), micro-
metastasis (0.2-2 mm) and even small tumour cells or
small clusters <0.2 mm (isolated tumour cells, ITC).
The hitherto published predictive factors for metastatic
disease in early HN tumours are histomorphological
parameters like mode of invasion (MOI; morphological
appearance of the infiltrating tumour front), depth of
tumour infiltration, grade of differentiation (GOD),
lymphatic invasion (LI) [5] and intratumoural lymphatic
density [6].
The ECAD glycoprotein (encoded by the CDH1 gene,
located on chromosome 16q22.1) is a Ca2+-dependent
intercellular adhesion molecule in epithelial cells, which
plays an important role in establishing and maintaining
intercellular connections and morphogenesis. The cyto-
plasmatic terminus of the ECAD molecule has been
shown to be linked to the actin cytoskeleton via a-catenin
and b-catenin [7].
Dysfunction of ECAD/catenin complex is directly
involved in carcinogenesis. CDH1 is considered to be a
tumour suppressor gene, whose loss has also been
demonstrated to promote tumour invasion and metasta-
sis in various cancer models [8]. There are several
mechanisms for abnormal ECAD expression in cancer,
including allelic loss at the CDH1 locus as well as somatic
and, rarely, germ line mutations. Transcriptional repres-
sion of ECAD by promoter hypermethylation has also
been reported in several tumour types and cell lines and
reduced expression of ECAD in esophageal Adenocarci-
noma was shown to correlate with poor prognosis [9,10].
Changes or alterations in the function and expression
of this cell to cell adhesion molecule have been postu-
lated to be an early event in the multiple step process of
tumour metastasis and an important factor in tumour
progression [10].
It is reported that down regulation of a-catenin and
b-catenin seems to be associated with dysfunction of
ECAD mediated cell adhesion and an increase in the
metastatic potential of cancer cells [11].
The correlation between the expression of the ECAD-
associated molecules and the presence of neck metasta-
sis is significant, indicating that reduced expression of
ECAD is a key function in the increased incidence of
neck metastasis [12].
In this study, we aimed to determine the potential of
ECAD expression in predicting early metastatic disease
of patients with HNSCC of the oral cavity and orophar-
ynx by analyzing a very well defined patient cohort (T1,
T2 oral cavity and oropharyngeal cancers) with meticu-
lous workup of sentinel lymph nodes.
The hypothesis was that low expression of ECAD
leads to reduced tumour cell to tumour cell adhesion
and therefore easier disintegration of single tumour cells
with increased risk of occult metastatic disease in ana-
logy to the results published by Hirata et al. for small
cell lung cancer [12].
Methods
Patients
Study permission was obtained by the local ethical
board commission of Zurich.
We retrospectively analyzed formalin-fixed, paraffin-
embedded primary tumour tissues of 120 patients for
ECAD expression. Thirteen patients had been excluded
in advance because of insufficient material on the paraf-
fin block of the primary tumour or lost follow up.
A majority of the patients in this study were partici-
pants in a prospective clinical trial of SNB of which the
results were already published [4].
In order to detect ECAD expression differences of the
primary tumour and the node metastases, we planned to
examine the corresponding lymph nodes of all patients
with occult metastatic disease (n = 45). Unfortunately
only in 10 patients there was enough material of the
sentinel lymph nodes to be analyzed at the same time
with the primary tumour, because no remaining material
was left for further immunohistochemistry.
Hundred-eleven patients were diagnosed and treated
in the ENT department of the University Hospital of
Zurich, nine at the Kantonsspital St. Gallen, Switzerland.
The ENT-clinic of the University Hospital Zurich is
one of the places with the largest single institution
experience in sentinel node biopsy for head and neck
cancers. Since the radioactive tracer is injected not
intraoperatively but in the awake patient, only tumours
of the oral cavity and the anterior oropharynx can be
accessed safely by the physician and without relevant
patient discomfort. We were aware that especially
tumours of the tonsillar pillar behave differently com-
pared to their oral cavity counterparts (HPV-Status);
however, we only included patients in the study with
“anterior oropharyngeal cancers” which encompasses
cancers localized on the anterior palatal arch and there-
fore most likely behave more like an oral cavity tumour
than a HPV-positive tonsillar carcinoma.
All patients were staged according to the guidelines of
the Swiss head and neck working group which corre-
sponds to the AJCC/UICC staging manual (7th edition
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2009). A detailed history was taken with special atten-
tion given to the exposure or use of tobacco and/or
alcohol. Clinical examination was amended with chest
radiograph, electrocardiogram, computed tomography
(CT) and/or magnetic resonance imaging (MRI) of the
head and neck. Additionally, every patient was examined
by ultrasound and fine needle aspiration cytology
(FNAC) in case of suspicious lymph nodes. In case of
positive nodal disease, patients were treated with selec-
tive neck dissection according to the primary tumour
locations or modified radical neck dissection and thus
excluded from the sentinel node biopsy study. A flow
diagram that illustrates the patients included and
excluded from the study is depicted in figure 1.
Inclusion criteria: - Patients with early stage (T1/T2)
SCC of the oral cavity or the oropharynx and clinical and
radiological negative regional disease (cN0)
- Patients who received lym-
phoscintigraphy and intraoperative sentinel node
dissection
Exclusion criteria: - Patients with advanced stage
(T3/T4) SCC of the oral cavity or oropharynx and clini-
cal and radiological negative regional disease (cN0) or
early stage primary tumour and clinically positive neck
disease (cN+)
- Patients who were treated by
radio-chemotherapy and not surgically
Clinical follow-up was available in all 120 patients
(mean clinical follow up 81 months; range 11-122
months).
Sentinel lymph node biopsy
The sentinel lymph node biopsy (SNB) procedure and
pathological work up of SLN has been recently reported
[4,13]. In brief, SNB was performed according to the fol-
lowing standardized protocol: The lymph node mapping
consisted of a preoperative lymphoscintigraphy and the
intraoperative use of a hand-held gammaprobe. The
location of the SLN was marked on the patient’s skin
under radiologic guidance. As the first surgical step, the
primary tumour was removed using a transoral
approach. For guidance to the SLN, two different hand-
held gammaprobes with collimated 14 mm tips were
used (Navigator GPS, Tyco Health Care Switzerland
Ltd, Wollerau, Switzerland and Neo 2000, Neoprobe
Corporation, Dublin, OH). The skin markings were
Figure 1 Consort Diagram of the patients included in the study. ECAD = E-Cadherin; IRS = Intensity Reactivity score; ITC = isolated tumour
cells
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confirmed with the gammaprobe and a small skin inci-
sion of 3 to 5 cm was made in a location that could be
extended for subsequent neck dissection. With the gui-
dance of the gammaprobe, the SLN was identified by
blunt dissection. In most cases, more than one SLN was
present. All the SLNs were excised selectively and the
activity level was measured ex situ. Lymph nodes were
considered to be SLNs if their activity counts were at
least three times the count of the background. In cases
where a subsequent neck dissection followed, the neck
dissection specimen was searched with the gammaprobe
for missed SLNs. Elective neck dissection comprised
levels I to III for oral cavity cancer and levels II to IV
for oropharyngeal cancer. SLNs were assessed intrao-
peratively with frozen section analysis. In case of detec-
tion of occult metastases, an immediate elective neck
dissection encompassing the above-mentioned levels
was performed in the same surgical session. For frozen
sections, each SLN was bisected and a fine slice of the
surface of each half was stained with hematoxylin and
eosin (H&E). The remainder of the SLNs were thawed
immediately and paraffin-embedded for complete histo-
pathologic evaluation. Extensive histopathologic work-
up of all SLNs and every node of the neck dissection
specimen was performed according to the same standar-
dized protocol. It is well known that the more precisely
the lymph nodes from a neck dissection specimen are
examined, the more metastases will be found [14].
Therefore, a very extensive histopathologic work-up of
all nodes was performed to achieve the highest possible
accuracy of results. The lymph nodes were first lamel-
lated manually into slices of 2 mm, and each slice was
step sectioned with the microtome at intervals of 150
μm. Each slice was stained with H&E and cytokeratin
for immunohistochemistry. The presence of occult
metastases was assessed and their size measured with a
standardized measuring ocular device. If no cytokeratin
positivity was found, the node was declared tumour free.
If cytokeratin deposits were detected, the positive sec-
tion was compared with the immediately adjacent serial
section previously stained with H&E to determine
whether the positivity was due to the presence of viable
tumour cells.
Tissue microarray construction
Paraffin-embedded tissue of 120 tumours was used for
the preparation of tissue microarray. A morphologically
representative region of the paraffin “donor” blocks was
chosen. From the representative region two core tissue
biopsies (diameter, 0.6 mm; height, 3-4 mm) from the
invading front were taken and precisely arrayed into a
new “recipient” paraffin block using a custom-built
instrument [15]. After the block construction was
completed, 4.0-μm sections of the resulting tumour tis-
sue microarray block were cut for further analysis.
Immunohistochemistry
ECAD immunohistochemistry was performed on paraf-
fin sections of formalin-fixed tissues, using the Cad-
herin-E antibody (1:200, Clone EP700Y, Cell Marque
Lifescreen Ltd.) and a Ventana Benchmark automated
staining system (Ventana Medical Systems) as recently
described [16,17].
Staining intensity was assessed using the Intensity
Reactivity Score (IRS), where staining intensity (SI) was
assessed to be negative (= 0), weak (= 1), moderate (=
2) or strong (= 3) and reactivity was determined by per-
centage of positive cells (PP) where negative specimens
were 0, 1-10% of cell (= 1), 11-30% (= 2), 31-50% (= 3),
51-80% (= 4) and >80% (= 5). IRS was calculated by
multiplying SI with PP resulting in a minimum of 0 and
a maximum of 15. Besides IRS, expression patterns were
assessed. Per patient, two samples were stained and
average IRS was taken for statistical analysis.
Tumours were categorized into ECAD low (IRS = 0-4),
moderate (IRS = 5-9) and high (IRS10-15).
Statistics
The relationship between ECAD expression and pre-
sence of lymph node metastasis was analyzed using
Fisher’s exact test. Subsequently, a logistic regression
was performed to evaluate the predictive power of
ECAD expression for lymph node metastasis while con-
trolling for differentiation grade and tumour stage.
Unfortunately, tumour differentiation grade could not
be included as a factor in the logistic regression model
because of quasi-complete separation in the data. The
potential usefulness of ECAD expression as a predictive
marker for lymph node metastasis was further specified
with details about sensitivity and specificity. True posi-
tive was defined as [number of individuals with low
expression/individuals with positive sentinel lymph
nodes]. False positive was defined as [number of indivi-
duals with low expression/individuals with negative
lymph nodes]. True negative and false negative was
defined accordingly (table 1).
Finally, a Kaplan-Meier survival analysis with calcula-
tion of log rank statistics was performed to compare
survival and relapse rates, respectively, between patients
with high and low expression. PASW Statistics 18.0.0
for windows (SPSS) was used for statistical analyses.
Results
Mean patient age was 59 years (range 28-88). The tumours
were located in the oral cavity (110/91.7%; mostly tongue)
and the oropharynx (10/8.3%). Male: Female ratio was
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82:38 (2.16:1). 63 patients presented with a T1 carcinoma,
55 with a T2 and in two cases T stage was not clearly
defined. Both sides (right vs. left) were involved equally
(46.7% vs. 42.5% respectively). In addition, 10.8% of
tumours were located in the midline.
T-stage (p = 0.252), gender (p = 1.000), tumour side
(p = 0.926) and location (p = 1.000) were not found to
correlate with positive lymph node status. Table 2 sum-
marizes the results of the clinical parameters.
Immunohistochemical ECAD expression of tumour
cells was predominantly membranous (figure 2). Some
undifferentiated SCC’s also showed cytoplasmatic stain-
ing. Forty-one of 120 (34.2%) of the primary tumours
were ECAD high. High ECAD expression was associated
with pathologic grade (table 2). No association between
ECAD expression and tumour stage was observed.
High ECAD expression was found to correlate with
negative lymph node status (P = 0.005) (table 2, figure
3). Even after controlling for tumour stage, ECAD
expression remained a significant predictor for lymph
node status (OR = 3.55, 95% CI: 1.450-8.694, P = 0.006;
table 3).
To assess the diagnostic accuracy of ECAD expression
as a predictive marker for SLN metastasis, sensitivity,
specificity, negative and positive predictive values were
determined. ECAD expression showed a sensitivity of
82.2% (95% CI: 0.674-0.915) and a specificity of 44%
(95% CI: 0.327-0.559) with respect to presence and
absence, respectively, of lymph node metastasis.
The positive predictive value was 66% and the nega-
tive predictive value was found to be 34.2%.
ECAD expression was also tested for a possible effect
on relapse rates. The log rank test however did not indi-
cate any influence of ECAD expression on relapse rates
(P = 0.105).
Discussion
In this study, we have confirmed our hypothesis and
demonstrated that downregulation of cancer cell-
expressed ECAD is associated with occult metastasis in
Table 1 Calculation of Sensitivity and Specificity depending on ECAD expression ("2x2 table”)
“gold standard” = result of sentinel node biopsy
occult metastatic disease:
Yes
occult metastatic disease:
No
new predictive marker for occult metastatic disease
(ECAD)
Low ECAD true positive false positive all test
positives
expression a b a + b
High
ECAD
c d all test
expression false negative true negative negatives
c + d
a + c b + d
all with occult all without occult
disease disease
Hypothesis: low ECAD expression (test) predicts occult metastatic disease.
sensitivity: a/(a + c).
specificity: d/(b + d).
Table 2 Association of E-cadherin with tumour stage, differentiation grade and lymph node status
Cadherin low (IRS ≤ 9)
n = 79 (65.8%)
Cadherin high (IRS > 9)
n = 41 (34.2%)
P-value
Tumor stage 0.4451)
pT1 40 (50.6%) 24 (58.5%)
pT2 39 (49.4%) 17 (41.5%)
Differentiation grade* 0.0182)
Grade I (well) 7 (9.5%) 7 (18.4%)
Grade II (moderate) 51 (68.9%) 29 (76.3%)
Grade III (poor) 16 (21.6%) 2 (5.3%)
Sentinel node 0.0051)
negative 42 (53.2%) 33 (80.5%)
positive 37 (46.8%) 8 (19.5%)
*Eight patients with differentiation grade not otherwise specified have been excluded.
1) Fisher’s exact test, 2) exact Mann-Whithey U test.
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oral cavity and oropharyngeal squamous cell carcinomas.
These findings support the function of ECAD in tumour
suppression and lymphogeneous metastasis in vivo.
In our study, approximately 90% of primary HNSCC
express ECAD to some degree, but high expression
levels have been shown to be significantly less associated
with lymph node metastasis.
Our data are consistent with other recent studies,
reporting low ECAD expression in squamous cell carcino-
mas of different organs to be correlated with invasion and
metastasis and worse outcome [18-23]. These findings
suggest that ECAD expression prohibits tumour disinte-
gration and metastasis. However, the exact molecular
function of cancer cell-expressed ECAD is currently
studied.
Along with down regulation of ECAD, a phenomenon
called Cadherin switching [24] namely the up regulation
of other members of the Cadherin family like N-Cad-
herin or P-Cadherin has been found, which is also asso-
ciated with worse outcome.
The problem of many study designs investigating predic-
tive markers is the heterogeneity of primary tumours
(location and T-stage) and N-stage which are lumped
together. Since patients qualifying for a sentinel node
biopsy yield a highly selected cohort (regarding tumour
location and N-Status) with no clinical evidence of lymph
node disease, we have as a consequence the possibility to
detect cancers with occult metastatic disease at one of its
earliest time points. Since we know that an existing
tumour dedifferentiates with time and more advanced
state, the possibility to find markers responsible for a
metastatic phenotype is most promising in a study setting
like ours. In this exceptionally well characterized and
homogeneous cohort, we were able to study the process of
early lymphatic metastasis and demonstrate a significant
association between cancer cell-expressed ECAD and
lymph node metastasis.
In the future, the combination of molecular markers
with proven predictive value for lymphatic disease like
ECAD, podoplanin [16,25], p16, bmi-1 [26], LOX [27]
Figure 2 2a strong, mainly membaneous ECAD expression; 2b
absent ECAD expression in another tumour; 2c negative control.
Figure 3 ECAD high-expressors where predominantly sentinel
node negative.
Table 3 Adjusted odds ratios (ORs), 95% confidence
intervals(95% CIs) and p-value of E-cadherin expression
and tumour stage as predictors for lymph node status.
Predictor OR 95% CI P-value
Cadherin expression
low vs. high 3.550 1.450-8.694 0.006
Tumour stage
pT1 vs. pT2 0.590 0.272-1.278 0.181
Logistic regression: Adjusted odds ratios (OR), 95% confidence intervals (95%
CI) and p-value of cadherin expression and tumor stage as predictors for
lymph node status. Because of quasi-complete separation in the data,
differentiation grade was not included as a factor in the logistic regression
model.
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and histopathological features as mentioned above,
could allow an individual risk stratification with possible
impact on treatment strategy.
Sentinel node biopsy has been successfully validated for
early HNSCC. However, use of SNB alone or SNB assisted
elective neck dissection is still controversially discussed for
staging and treatment of the cN0 neck in patients with
early HNSCC. Additional biomarkers may be of help for
better stratification of patients selected for SNB in contrast
to elective neck dissection. The hitherto published predic-
tive factors for metastatic disease in SNB include histo-
morphological parameters of the primary tumour like
mode of invasion (MOI; morphological appearance of the
infiltrating tumour front), grade of differentiation (GOD),
lymphatic invasion (LI) [5] and intratumoural lymphatic
density [6].
ECAD is a potential additional marker, because down-
regulation of ECAD indicates an increased risk for
lymph node metastasis. In the future, a combination of
molecular markers like ECAD expression, and histomor-
phologic parameters may be used to stratify patients
according to their risk for occult nodal disease.
Conclusion
In summary, we provide evidence that downregulation
of cancer cell-expressed ECAD correlates with higher
incidence of lymph node metastasis in early HNSCC of
the oral cavity and oropharynx. While ECAD might not
be applicable as a predictive marker in a single test,
ECAD immunohistochemistry might contribute among
other factors to select patients for either elective neck
dissection, sentinel lymph node biopsy or wait-and-
watch policy.
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